Second-generation antipsychotics in dementia: Beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials

Psychopharmacology

Volumn 212, Issue 2, 2010, Pages 119-129

  Gentile, Salvatore ^a  

^a ASL Salerno 1   (Italy)

Author keywords

Alzheimer; Behavioural symptoms; Dementia; Neuropsychiatric symptoms; Second generation antipsychotics

Indexed keywords

ARIPIPRAZOLE; CITALOPRAM; CLOZAPINE; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; ZIPRASIDONE;

ALZHEIMER DISEASE; BEHAVIOR DISORDER; BEHAVIOR THERAPY; CAREGIVER BURDEN; CLINICAL TRIAL; COCHRANE LIBRARY; COGNITIVE DEFECT; DEMENTIA; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EMBASE; HUMAN; INFORMATION RETRIEVAL; MEDLINE; MENTAL DISEASE; METHODOLOGY; PRIORITY JOURNAL; PSYCHOSIS; PSYCINFO; PUBLICATION; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW;

EID: 77957354072     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-1939-z     Document Type: Review

References (79)

1. GS Alexopoulos J Stremi D Carpenter JP Docherty 2004 Using antipsychotic agents in older patients J Clin Psychiatry 65 Suppl 2 1 105
2. C Ballard R Howard 2006 Neuroleptic drugs in dementia: benefits and harm Nat Rev Neurosci 7 492 500 1:CAS:528:DC%2BD28Xkslelu7Y%3D 10.1038/nrn1926 16715057
3. Ballard C, Waite J (2006) The effectiveness of atypical antipsychotics for the treatment of psychosis in Alzheimer's disease. Cochrane database Syst Rev Art. No: CD003746. doi: 10.1002/4651858.CD003476.pub2.
4. C Ballard A Thomas J Fossey L Lee R Jacoby MM Lana, et al. 2004 A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cut-off is a predictor of clinical outcome J Clin Psychiatry 65 114 119 10.4088/JCP.v65n0120 14744180
5. C Ballard MM Lana E Juszczak S Douglas A Swann A Thomas, et al. 2005 Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomized double-blind placebo controlled trial BMJ 330 7496 874 1:CAS:528:DC%2BD2MXktlegtrg%3D 10.1136/bmj.38369.459988.8F 15722369 (Pubitemid 40545686)
6. C Ballard MM Lana M Theodoulou S Douglas R McShane R Jacoby, et al. 2008 A randomized, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD Trial) PLos Med 5 587 599 1:CAS:528:DC%2BD1cXmvVSltLw%3D 10.1371/journal.pmed.0050076 (Pubitemid 351649258)
7. C Ballard ML Hanney M Theodoulou S Douglas R McShane K Kossakowski, et al. 2009 The dementia antipsychotic withdrawal trial (DART-AD): long term follow-up of a randomized placebo-controlled trial Lancet Neurol 8 151 157 1:CAS:528:DC%2BD1MXisFCgu7o%3D 10.1016/S1474-4422(08)70295-3 19138567
8. J Battaglia SR Lindborg K Alaka K Meehan P Wright 2003 Calming versus sedative effects of intramuscular olanzapine in agitated patients Am J Emerg Med 21 192 198 10.1016/S0735-6757(02)42249-8 12811711 (Pubitemid 36734681)
9. SJ Bell HT Taipale H Soini KH Pìtkälä 2010 Sedative load among long-term care facility residents with and without dementia. A cross-sectional study Clin Drug Inv 30 1 63 70 10.2165/11531460-000000000-00000
10. H Brodaty D Ames J Snowdon M Woodward J Kirwan R Clarnette, et al. 2003 A randomized of risperidone for the treatment of aggression, agitation, and psychosis of dementia J Clin Psychiatry 64 134 143 1:CAS:528: DC%2BD3sXitlWjsLw%3D 10.4088/JCP.v64n0205 12633121
11. H Brodaty D Ames J Snowdon M Woodward J Kirwan R Clarnette, et al. 2005 Risperidone for psychosis of Alzheimer's disease and mixed dementia; results from a double-blind, placebo-controlled trial Int J Geriatr Psychiatry 20 1153 1157 10.1002/gps.1409 16315159 (Pubitemid 43040682)
12. R Bullock 2005 Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings Curr Med Res Opin 21 1 1 10 1:CAS:528:DC%2BD2MXislCmtro%3D 10.1185/030079904X16777 15881470
13. S Carson MS McDonagh K Peterson 2006 A systematic review of efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia J Am Geriatr Soc 54 354 361 10.1111/j.1532-5415.2005.00566. x 16460391
14. W Chan LC Lam CN Choy VP Leung S Li F Chiu 2001 A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients Int J Geriatr Psychiatry 16 1156 1162 1:STN:280:DC%2BD3MnpvF2ktA%3D%3D 10.1002/gps.504 11748775 (Pubitemid 34044183)
15. WS Clark JS Street PD Feldman A Breier 2001 The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease J Clin Psychiatry 62 34 40 1:CAS:528:DC%2BD3MXhsVWqs70%3D 10.4088/JCP.v62n0108 11235926
16. D Craig A Mirakhur DJ Hart SP McIlroy AP Passmore 2005 A cross sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer's disease Am J Geriatr Psychiatry 13 460 468 15956265
17. JL Cummings J Street D Masterman WS Clark 2002 Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies Dement Geriatr Cogn Disord 13 67 73 1:CAS:528:DC%2BD38XhtFOruro%3D 10.1159/000048636 11844887 (Pubitemid 34161150)
18. PP De Deyn A Rasmussen JP Bocksberger PLJ Dautzenberg S Eriksson BA Lawlor 1999 A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia Neurology 53 946 955 10496251
19. De Deyn P, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD, et al (2004) Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Ger Psychiatry 19:115-126
20. P De Deyn DV Jeste R Swanink D Kostic C Breder WH Carson, et al. 2005 Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease J Clin Psychopharmacology 25 463 467 10.1097/01.jcp.0000178415.22309.8f (Pubitemid 41368369)
21. WG Deberdt MW Dysken SA Rappaport PD Feldman CA Young DP Hay, et al. 2005 Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia Am J Geriatr Psychiatry 13 722 730 16085789
22. RS Doody JC Stevens RM Dubinsky L Kaye L Gwyther RC Mohs, et al. 2001 Practice parameter: management of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 56 1154 1166 1:STN:280:DC%2BD3MzntFantw%3D%3D 11342679
23. CP Ferri M Prince C Brayne H Brodaty L Fratiglioni M Ganguli, et al. 2005 Alzheimer's Disease International. Global prevalence of dementia: a Delphi consensus study Lancet 366 2112 2117 10.1016/S0140-6736(05)67889-0 16360788 (Pubitemid 41797645)
24. S Finkel C Kozma S Long A Greenspan R Mahmoud O Baser, et al. 2005 Risperidone treatment in elderly patients: relative risk of cerebrovascular events versus other antipsychotics Int Psychogeriatr 17 4 617 629 10.1017/S1041610205002280 16202186 (Pubitemid 41758766)
25. CS Fontaine LS Hynan K Koch K Martin-Cook D Svetlik MF Weiner 2003 A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities J Clin Psychiatry 64 726 739 1:CAS:528:DC%2BD3sXls12ktbg%3D 10.4088/JCP.v64n0617 12823090
26. L Frank L Kleinman G Ciesla MFT Rupnov H Brodaty 2004 The effect of risperidone on nursing burden associated with caring for patients with dementia J Am Geriatr Soc 52 1449 1455 10.1111/j.1532-5415.2004.52406.x 15341545 (Pubitemid 39209591)
27. P Gareri A Cotroneo R Lacava G Seminara N Marigliano A Loiacono, et al. 2004 Comparison of the efficacy of new conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia Arch Gerentol Geriatr 9 suppl. 1 207 215 1:CAS:528:DC%2BD2cXltVChtrY%3D 10.1016/j.archger. 2004.04.029 (Pubitemid 38822869)
28. S Gentile 2007 Atypical antipsychotic for the treatment of bipolar disorder. More shadows than lights CNS Drugs 21 5 367 387 1:CAS:528: DC%2BD2sXmvVKgsbw%3D 10.2165/00023210-200721050-00002 17447826 (Pubitemid 46705301)
29. Gentile S (2009) Second-generation antipsychotics in bipolar disorder, two years later: the song remains the same. Sociedad Iberoamericana de Información Cientifica www.siicsalud.com/des/expertocompleto.php/101621
30. SS Gill PA Rochon N Herrmann PE Lee K Sykora N Gunraj, et al. 2005 Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study BMJ 10.1136/bmj.38330.470486.8F (Pubitemid 40314208)
31. F Grossman A Okamoto 2004 Risperidone in the treatment of elderly patients with psychosis of Alzheimer's disease and related dementias J Am Geriatr Soc 52 4 852 853 10.1111/j.1532-5415.2004.52230-12.x 15086685 (Pubitemid 38596518)
32. N Herrmann M Mamdani KL Lanctôt 2004 Atypical antipsychotics and risk of cerebrovascular accidents Am J Psychiatry 161 1113 1115 10.1176/appi.ajp.161.6.1113 15169702 (Pubitemid 38736000)
33. C Holmes D Wilkinson C Dean C Clare M El-Oki C Hensford, et al. 2007 Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study Int J Geriatr Psychiatry 22 380 381 10.1002/gps.1667 17380475 (Pubitemid 46680850)
34. RJ Howard E Juszczak CG Ballard P Bentham RG Brown R Bullock, et al. 2007 Donezepil for the treatment of agitation in Alzheimer's disease New Engl J Med 357 14 1382 1392 1:CAS:528:DC%2BD2sXhtFeisLvL 10.1056/NEJMoa066583 17914039 (Pubitemid 47535593)
35. IR Katz DV Jeste JE Mintzer C Clyde J Napoletano M Brecher for the Risperidone Study Group 1999 Comparison of risperidone and placebo for psychosis and behavioural disturbances associated with dementia: a randomised, double-blind trial J Clin Psychiatry 60 107 115 1:CAS:528:DyaK1MXhvVSiur0%3D 10084637
36. J Kennedy W Deberdt A Siegal J Micca E Degenhardt J Ahl, et al. 2005 Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia Int J Geriatr Psychiatry 20 1020 1027 10.1002/gps.1397 16250069 (Pubitemid 41723572)
37. R Kurlan J Cummings R Raman L Thal for the Alzheimer's Disease Cooperative Group 2007 Quetiapine for agitation or psychosis in patients with dementia and parkinsonism Neurology 68 1356 1363 1:CAS:528:DC%2BD2sXktlSms7s%3D 10.1212/01.wnl.0000260060.60870.89 17452579 (Pubitemid 46659086)
38. MM Lana A Swann J O'Brien A Fairbairn K Reichell 2001 Prevalence and pharmacological management of behavioral and psychological symptoms amongst dementia suffers living in care environments Int J Geriatr Psychiatry 16 39 44 10.1002/1099-1166(200101)16:1<39::AID-GPS269>3.0.CO;2-F (Pubitemid 32111815)
39. P Lee SS Gill M Freedman SE Bronskill MP Hillmer PA Rochon 2004 Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review BMJ 10-1136/bmj.38125.465579.55
40. DL Leslie S Mohamed RA Roseneck 2009 Off-label use of antipsychotic medications in the Department of Veteran Affairs Health Care System Psychiatr Serv 60 1175 1181 10.1176/appi.ps.60.9.1175 19723731
41. R Liperoti G Gambassi KL Lapane C Chiang C Pedone V Mor, et al. 2005 Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics J Clin Psychiatry 66 1090 1096 10.4088/JCP.v66n0901 16187764
42. R Liperoti G Onder F Landi KL Lapane V Mor R Bernabei, et al. 2009 All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study J Clin Psychiatry 70 1340 1347 10.4088/JCP.08m04597yel 19906339
43. G Livingston AE Walker CLE Fatona C Cooper 2007 Antipsychotics and cognitive decline in Alzheimer's disease: the LASER- Alzheimer's disease longitudinal study J Neurol Neurosurg Psychiatry 78 25 29 1:STN:280: DC%2BD28jjs1Sntg%3D%3D 10.1136/jnnp.2006.094342 16801350 (Pubitemid 46048258)
44. AM McGrath GA Jackson 1996 Survey of prescribing in residents of nursing home in Glasgow BMJ 314 611 612
45. IG McKeith EK Perry RH Perry 1999 Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies Neurology 53 5 902 905 1:STN:280:DyaK1MvisVGlsA%3D%3D 10496243
46. KM Meehan H Wang SR David JR Nisivoccia B Jones CM Beasley Jr, et al. 2002 Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia Neuropsychopharmacology 26 494 504 1:CAS:528:DC%2BD38XitlGhu78%3D 10.1016/S0893-133X(01)00365-7 11927174 (Pubitemid 34260999)
47. PP Mintzer MM Carrasco W Deberdt C Jaendel DP Hay PD Feldman, et al. 2004 Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease Int J Geriatr Psychiatry 19 115 126 10.1002/gps.1032 (Pubitemid 38247846)
48. J Mintzer A Greenspan I Caers I Van Hove S Kushner M Weiner, et al. 2006 Risperidone in the treatment of psychosis of Alzheimer disease Am J Geriatr Psychiatry 14 280 291 10.1097/01.JGP.0000194643.63245.8c 16505133
49. JA Mintzer LE Tune CD Breder R Swanick RN Marcus RD McQuade, et al. 2007 Aripiprazole for the treatment of psychosis in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses Am J Geriatr Psychiatry 15 918 931 10.1097/JGP.0b013e3181557b47 17974864
50. A Mowla A Pani 2010 Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease. A double-blind, randomized clinical trial J Clin Psychopharmacol 30 40 43 1:CAS:528:DC%2BC3cXlvFalsw%3D%3D 10.1097/JCP.0b013e3181ca0c59 20075646
51. BH Mulsant GM Gharabawi CA Bossie L Mao RA Martinez LE Tune, et al. 2004 Correlates of anticholinergic activity in patients with dementia and risperidone treated with risperidone or olanzapine J Clin Psychiatry 65 1708 1714 1:CAS:528:DC%2BD2MXpsFWiug%3D%3D 10.4088/JCP.v65n1217 15641877
52. DL Murman Q Chen MC Powell SB Kuo CJ Bradley CC Colenda 2002 The incremental direct costs associated with behavioral symptoms in Alzheimer's disease Neurology 59 1721 1729 1:STN:280:DC%2BD38jhtFyhuw%3D%3D 10.1001/archneur.59.11.1721 12473759 (Pubitemid 35340481)
53. D Paleacu Y Barak I Mirecky D Mazeh 2008 Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients. A 6-week, double-blind, placebo controlled study Int J Geriatr Psychiatry 23 393 400 1:STN:280:DC%2BD1c3isVCltw%3D%3D 10.1002/gps.1892 17879256 (Pubitemid 351566336)
54. BG Pollock BH Mulsant J Rosen S Mazumdar RE Blakesley PR Houck, et al. 2007 A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia Am J Geriatr Psychiatry 15 942 952 10.1097/JGP.0b013e3180cc1ff5 17846102
55. M Rainer M Haushofer H Pfolz C Struhal W Wick 2007 Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety, and cognitive functions Eur Psychiatry 22 395 403 1:STN:280:DC%2BD2srlsVOnsQ%3D%3D 10.1016/j.eurpsy.2007.03.001 17482432 (Pubitemid 47391218)
56. SA Rappaport RN Marcus G Manos RD McQuade DA Oren 2009 A randomized, double-bind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer's, vascular, or mixed dementia J Am Med Dir Assoc 10 21 27 10.1016/j.jamda.2008.06.006 19111849
57. RA Rosenhek DL Leslie JL Sindelar EA Miller PN Tariot KS Dagerman, et al. 2007 Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression inn Alzheimer disease Arch Gen Psychiatry 64 11 1259 1268 10.1001/archpsyc.64.11.1259 (Pubitemid 350074824)
58. Rossom RC, Rector TS, Lederle FA, Dysken MW (2010) Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia? J Am Geriatr Soc: In press
59. S Ruths J Straand HA Nygaard D Aarsland 2008 Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study. The Bergen District Nursing Home Study (BEDNURS) Int J Geriatr Psychiatry 23 889 895 10.1002/gps.1998 18306150
60. LS Schneider VE Pollock SA Lyness 1990 A metaanalysis of controlled trials of neuroleptic treatment in dementia J Am Geriatr Soc 38 553 563 1:STN:280:DyaK3c3jslektg%3D%3D 1970586
61. LS Schneider KS Dagerman P Insel 2005 Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized, placebo-controlled trials JAMA 294 1934 1943 1:CAS:528:DC%2BD2MXhtFCitLnK 10.1001/jama.294.15.1934 16234500 (Pubitemid 41464695)
62. LS Schneider KS Dagerman P Insel 2006 Efficacy and adverse events of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials J Am Geriatr Psychiatry 14 191 210
63. LS Schneider PN Tariot KS Dagerman SM Davis JK Hsiao S Ismail for the CATIE-AD Study group, et al. 2006 Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease New Engl J Med 355 15 1525 1538 1:CAS:528:DC%2BD28XhtVyhtrfE 10.1056/NEJMoa061240 17035647 (Pubitemid 44547805)
64. R Schulz AT O'Brien J Bookwala K Fleisser 1995 Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes Gerontologist 35 771 791 1:STN:280:DyaK287islKqsA%3D%3D 8557205
65. KM Sink KF Holden K Yaffe 2005 Pharmacological treatment of neuropsychiatric symptoms of dementia. A review of evidence JAMA 293 596 608 1:CAS:528:DC%2BD2MXhtVWqsbc%3D 10.1001/jama.293.5.596 15687315 (Pubitemid 40171242)
66. Y Stern MX Tang MS Albert J Brandt DM Jacobs K Bell, et al. 1997 Predicting time to nursing home care and death in individuals with Alzheimer disease JAMA 227 806 812 10.1001/jama.277.10.806
67. JS Street S Clark KS Gannon JL Cummings FP Bymaster RN Tamura, et al. 2000 Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities Arch Gen Psychiatry 57 968 976 1:CAS:528:DC%2BD3cXnsFenur0%3D 10.1001/archpsyc.57.10.968 11015815
68. JE Streim AP Porteinsson CD Breder R Swanink R Marcus R McQuade, et al. 2008 A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer Disease Am J Geriatr Psychiatry 16 357 550 10.1097/JGP.0b013e318165db77
69. GH Suh HG Son YS Ju KH Jcho BK Yeon YM Shin, et al. 2004 A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances Am J Geriatr Psychiatry 12 509 516 15353389
70. DL Sultzer SM Davis PN Tariot KS Dagerman BD Lebowitz CG Lyketsos for the CATIE-AD Study group 2008 Clinical symptoms responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial Am J Psychiatry 165 844 854 10.1176/appi.ajp.2008.07111779 18519523 (Pubitemid 351948716)
71. PN Tariot L Schneidr IR Katz JE Mintzer J Street M Copemhaver, et al. 2006 Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial Am J Geriatr Psychiatry 14 767 776 10.1097/01.JGP.0000196628.12010.35 16905684 (Pubitemid 44380069)
72. L Teri RG Logsdon E Peskind M Raskind MF Weiner RE Tractemberg, et al. 2000 Treatment of agitation in AD. A randomized, placebo-controlled trial Neurology 55 1271 1278 1:CAS:528:DC%2BD3cXos12gtLw%3D 11087767
73. US Food and Drug Administration. Deaths with antipsychotics in elderly patients with behavioral disturbances. 2005. US Food and Drug Administration, FDA Public Health Advisory, Centre for Drug Evaluation and Researches. http://www.fda.gov/Cder/drug/advisory/antipsychotics.htm. Accessed: February 21, 2008.
74. FRJ Verhey M Verkaaik R Lousberg on behalf of the Olanzapine-Haloperidol in Dementia Study Group 2008 Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results from a randomized controlled double-blind trial Dement Geriatr Cogn Disord 21 1 8 10.1159/000089136
75. PS Wang S Schneeweiss J Avorn MA Fischer H Mogun DH Solomon, et al. 2005 Risk of death in elderly users of conventional vs. atypical antipsychotic medications New Engl J Med 353 2335 2341 1:CAS:528:DC%2BD2MXht1OmsbrI 10.1056/NEJMoa052827 16319382 (Pubitemid 41713745)
76. E Wooltorton 2002 Risperidone (Risperdal): increased incidence of cerebrovascular events in dementia trials CMAJ 167 11 1269 1270 12451085
77. E Wooltorton 2004 Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials CMAJ 170 9 1395 15111472
78. L Zheng WJ Mack KS Dagerman JK Hsiao BD Lebowitz CG Lyketsos, et al. 2009 Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD Study Am J Psychiatry 166 583 590 10.1176/appi.ajp.2008.08081218 19369318
79. KX Zhong PN Tariot J Mintzer MC Minkwitz NA Devine 2007 Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled trial Curr Alzh Res 4 81 93 1:CAS:528:DC%2BD2sXht1Wjsr0%3D 10.2174/ 156720507779939805 (Pubitemid 46293886)